3702-12-3

Usage

Uses

Used in Pharmaceutical Industry:
3-ISO-PROPYL-1-METHYL-1H-PYRAZOL-5-AMINE is used as a sedative-hypnotic agent for the treatment of insomnia. It is utilized for its ability to enhance the activity of GABA, thereby promoting sleep and reducing anxiety in patients suffering from sleep disorders.
Used in Sleep Aid Formulations:
3-ISO-PROPYL-1-METHYL-1H-PYRAZOL-5-AMINE is used as an active ingredient in sleep aid formulations to help individuals with insomnia achieve a restful night's sleep. Its mechanism of action involves the modulation of GABAergic neurotransmission, which contributes to its sedative and hypnotic effects.
Used in Anxiety Management:
3-ISO-PROPYL-1-METHYL-1H-PYRAZOL-5-AMINE is also used in the management of anxiety, particularly in cases where sleep disturbances are associated with anxiety disorders. Its anxiolytic properties, derived from its interaction with the GABA system, make it a suitable option for reducing anxiety levels and improving sleep quality.

Upstream product

• 29509-06-6 4-methyl-3-oxopentanonitrile 
• 60-34-4 methylhydrazine 

Downstream Products

• 93181-38-5 3-Isopropyl-1,6-dimethyl-4-(3-nitro-phenyl)-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester; hydrochloride 
• 884316-48-7 2-(1-methyl-3-isopropylpyrazol-5-ylamino)benzoic acid 
• 947299-01-6 1-methyl-3-isopropyl-4-cyclohexenyl-5-amino-1H-pyrazole 
• 93181-75-0 4,7-dihydro-1,6-dimethyl-3-(1-methylethyl)-4-(3-trifluoromethylphenyl)-1H-pyrazolo[3,4-b]-pyridin-5-carboxylic acid ethyl ester, hydrochloride 
• 93181-73-8 4,7-dihydro-1,6-dimethyl-3-(1-methylethyl)-4-(2-nitrophenyl)-1H-pyrazolo[3,4-b]pyridin-5-carboxylic acid (1-methylethyl) ester, hydrochloride 
• 93199-01-0 4,7-Dihydro-1,6-dimethyl-3-(1-methylethyl)-4-(2-nitrophenyl)-1H-pyrazolo[3,4-b]pyridin-5-carboxylic acid 2-methoxyethyl ester, hydrochloride 
• 93181-74-9 4,7-dihydro-1,6-dimethyl-3-(1-methylethyl)-4-(2-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-5-carboxylic acid ethyl ester, hydrochloride 
• 93181-72-7 4,7-dihydro-1,6-dimethyl-3-(1-methylethyl)-4-(2-nitrophenyl)-1H-pyrazolo[3,4-b]pyridin-5-carboxylic acid ethyl ester, hydrochloride 

Relevant academic research and scientific papers

HSP90 INHIBITORS AND USES THEREOF

Herein is described the design and synthesis of resorcylate aminopyrazole compounds. These compounds show broad, potent and fungal-selective Hsp90 inhibitory activity. These compounds also find use in treating Hsp90 related deseases.

Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors

The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone is also critically important, however, to the pathogen's hu

Application of 5-aminopyrazole compounds to plant growth regulation aspect

The invention discloses application of 5-aminopyrazole compounds to plant growth regulation aspect in the technical field of pesticide compounds, in particular to application of the 5-aminopyrazole compounds shown by the formula to the plant growth regulation aspect, particularly the application to the plant growth inhibition. The formula I is shown in the description. The compound shown in the formula I can be used as a weedicide; weeds in places such as highway and railway can be killed through regulating the concentration of the 5-aminopyrazole compounds, wherein the R1 is hydrogen or alkylor phenyl or substituted phenyl; R2 is alkyl; R3 is hydrogen or halogen.

Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model

Psoriasis is a chronic T-cell-mediated autoimmune disease, and FMS-like tyrosine kinase 3 (FLT3) has been considered as a potential molecular target for the treatment of psoriasis. In this investigation, structural optimization was performed on a lead compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (1), which showed a moderate inhibitory activity againt FLT3. A series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis led to the discovery of a number of potent FLT3 inhibitors. One of the most active compounds, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-3-fluorophenyl)-3-(5-tert-butylisoxazol-3-yl)urea (18b), was then chosen for in-depth antipsoriasis studies because this compound displayed the highest potency in a preliminary antipsoriasis test. Compound 18b exhibited significant antipsoriatic effects in the K14-VEGF transgenic mouse model of psoriasis, and no recurrence was found 15 days later after the last administration. Detailed mechanisms of action of compound 18b were also investigated. Collectively, compound 18b could be a potential drug candidate for psoriasis treatment.

9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS

The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, A, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

PYRAZOLE DERIVATIVES

Disclosed are compounds of general formula (I), wherein R, R1, Rc, Rd, Re, Rf, X, Y, Z, A and B are as defined in the application.

PYRAZOLE DERIVATIVES

Disclosed are compounds of general formula (I), wherein R, R1, Rc, Rd, Re, Rf, X, Y, Z, A and B are as defined in the application.

Pharmacologically active pyrazolopyridines

The present invention is directed to new 4,7-dihydro-pyrazolo[3,4-b]pyridines. The compounds possess Ca2+ -antagonist, antihypertensive, vasodilating and antiangina activity. A process for producing them as well as pharmaceutical compositions containing them are also described.

4,7-dihydropyrazolo(3,4-b) pyridine derivatives

Novel Ca-blockers, 4,7-dihydropyrazolo[3,4-b]pyridine derivatives having potent antihypertensive and coronary vasodilating actions and useful in treatment for diseases in circulatory system, but without systole inhibitory action.